Search research articles
Contact Us
Filters
Showing results (221-230 of 635) with videos related to
Page
of 64
Sort By:
Diabetologia
|
August 20, 2021
Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
Taha Sen, Jingwei Li, Brendon L Neuen, et al.
American Heart Journal
|
April 30, 2017
An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome
Neha J Pagidipati, Connie N Hess, Robert M Clare, et al.
Journal of the American College of Cardiology
|
November 6, 2012
Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction
Sergio Leonardi, Laine Thomas, Megan L Neely, et al.
The American Journal of Cardiology
|
August 30, 2008
Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV)
James M Yau, John H Alexander, Gail Hafley, et al.
Journal of Thrombosis and Thrombolysis
|
May 10, 2006
Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative
Kanwar P Singh, Matthew T Roe, Eric D Peterson, et al.
Contemporary Clinical Trials
|
July 23, 2008
Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX library
Kenneth W Mahaffey, Craig J Reist, Yuling Fu, et al.
The Lancet. Diabetes & Endocrinology
|
September 10, 2019
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
Brendon L Neuen, Tamara Young, Hiddo J L Heerspink, et al.
European Journal of Heart Failure
|
June 27, 2024
Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial
Muthiah Vaduganathan, Christopher P Cannon, Meg J Jardine, et al.
American Heart Journal
|
August 1, 2006
Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview
Kenneth W Mahaffey, Frans Van de Werf, Stanton K Shernan, et al.
American Heart Journal
|
June 2, 2015
The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations
Matthew T Roe, Kenneth W Mahaffey, Justin A Ezekowitz, et al.
Page
of 64
Search research articles
Search
Showing results (221-230 of 635) with videos related to
Sort By:
Page
of 64
Diabetologia
|
August 20, 2021
Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
Taha Sen, Jingwei Li, Brendon L Neuen, et al.
American Heart Journal
|
April 30, 2017
An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome
Neha J Pagidipati, Connie N Hess, Robert M Clare, et al.
Journal of the American College of Cardiology
|
November 6, 2012
Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction
Sergio Leonardi, Laine Thomas, Megan L Neely, et al.
The American Journal of Cardiology
|
August 30, 2008
Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV)
James M Yau, John H Alexander, Gail Hafley, et al.
Journal of Thrombosis and Thrombolysis
|
May 10, 2006
Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative
Kanwar P Singh, Matthew T Roe, Eric D Peterson, et al.
Contemporary Clinical Trials
|
July 23, 2008
Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX library
Kenneth W Mahaffey, Craig J Reist, Yuling Fu, et al.
The Lancet. Diabetes & Endocrinology
|
September 10, 2019
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
Brendon L Neuen, Tamara Young, Hiddo J L Heerspink, et al.
European Journal of Heart Failure
|
June 27, 2024
Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial
Muthiah Vaduganathan, Christopher P Cannon, Meg J Jardine, et al.
American Heart Journal
|
August 1, 2006
Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview
Kenneth W Mahaffey, Frans Van de Werf, Stanton K Shernan, et al.
American Heart Journal
|
June 2, 2015
The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations
Matthew T Roe, Kenneth W Mahaffey, Justin A Ezekowitz, et al.
Page
of 64